arrow
A

Ayalew Tefferi

Mayo Clinic
H指数:152
被引数:10.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic impact of need for re-induction based on day-14 residual disease and age-adapted consolidation strategy in acute myeloid leukemia

基于第14天残留病灶和年龄适应巩固策略的再诱导需求对急性髓系白血病预后的影响

2026-09-300
OAAI
Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients

维奈克拉联合去甲基化药物用于新诊断急性髓系白血病7天、14天、21天及28天疗程:基于ELN和Mayo遗传风险分层的540例患者分析

2026-09-180
PRE
Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia

356例新诊断急性髓系白血病患者一线维奈克拉联合去甲基化药物治疗失败后的生存影响因素

2026-08-170
OAAI
Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients

慢性髓系单核细胞白血病患者行异基因干细胞移植与未移植者的风险调整生存比较:梅奥诊所775例连续患者的经验

2026-07-280
PRE
ICC/WHO-Defined and NGS-Annotated Idiopathic Hypereosinophilia (iHES/iHE): Mutations, Clinical and Treatment Details, and Predictors of Survival

国际细胞遗传学协作组/世界卫生组织定义和下一代测序注释的原发性嗜酸性粒细胞增多症(iHES/iHE):突变、临床和治疗细节及生存预测因素

2026-06-190
OAAI
Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities

真性红细胞增多症和原发性血小板增多症中的自身免疫和炎症性疾病:对疾病结局和合并症的影响

2026-04-170
OAAI
CMML2AML: machine-learning discovery of co-mutations and specific single mutations predictive of blast transformation in chronic myelomonocytic leukemia

CMML2AML:机器学习发现与慢性骨髓单核细胞白血病blast transformation相关的共突变和特异性单突变

2026-04-120
OAAI
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients

CPX-351(脂质体阿糖胞苷和柔红霉素)与维奈克拉联合表观遗传药物疗法在初诊急性髓系白血病中的比较:一项涉及600例梅奥诊所患者的回顾性比较研究

2026-04-060
OAAI
One vs. 2 vs. ≥3 TET2 mutations in chronic myelomonocytic leukemia: co-mutation patterns and prognostic relevance in the context of contemporary prognostic models including BLAST-mol and CPSS-mol

慢性髓单核细胞白血病患者中1个、2个或≥3个TET2突变的比较:在包括BLAST-mol和CPSS-mol在内的当代预后模型背景下,探讨共突变模式及预后相关性

2026-04-040
OAAI
Clinical Experience With Venetoclax-Based Combinations for Relapsed/Refractory or MRD-Positive NPM1-Mutated Acute Myeloid Leukemia

基于Venetoclax的联合方案在复发/难治或MRD阳性NPM1突变急性髓系白血病中的临床经验

2026-04-010
OAAI
TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent

TP53突变和循环 blasts ≥20% 是接受一线维奈克拉联合去甲基化药物治疗加速期/原始细胞期骨髓增殖性肿瘤患者生存的主要决定因素

2026-02-180
OAAI